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ADULT ADHD AND AFFECTIVE TEMPERAMENT: A COHORT STUDY 
 
 
SIVAN MAUER 
 
ABSTRACT  
 It has been suggested that adult attention-deficit/hyperactivity disorder (ADHD) 
may reflect affective temperaments, which involve mild manic and/or depressive traits as 
part of one’s personality.  Such innate traits are associated with poor attention. Stimulant 
medications, given for ADHD, can worsen manic symptoms, thereby worsening 
attentional symptoms paradoxically, by worsening the underlying mood condition that 
causes poor attention.  
 This study examines the nature of response to stimulant medication in subjects 
with affective temperament (Cyclothymia, Hyperthymia, Dysthymia). 
 A retrospective cohort study was conducted of 87 subjects from Tufts Medical 
Center Mood Disorders Program.  Subjects were included if they had ever been 
prescribed stimulant medications.  Prior diagnosis of adult ADHD, or not, also was 
assessed.  This sample was assessed using TEMPS-A scale to measure affective 
temperaments, and the CGI-I scale to assess clinical change in mood/anxiety and 
attention/cognition. 
 Data analysis was conducted using descriptive statistics and stratification. This 
study has several limitations. Researchers and subjects were not blinded; all subjects 
received stimulants, with no non-stimulant control group; and treatment response was 
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assessed retrospectively. Nonetheless, no such data exist in the scientific literature 
previously, and thus this pilot data adds to our present knowledge. 
 61% of the sample had an affective temperament  (using the strictest definition of 
75% or more TEMPS items endorsed). Of these, the most common was cyclothymic 
(40%) followed by hyperthymic (24%). 
 The main treatment results were that most patients (55%) had no effect on 
mood/anxiety, but a large number (43%) had worsening mood/anxiety symptoms. 37% 
had mild or moderate improvement in cognition. 
 Stratified by ADHD diagnosis, stimulant effects were somewhat better with, than 
without, ADHD diagnosis, for cognition but not for mood/anxiety.  In ADHD subjects, 
49% had worsening mood and/or anxiety symptoms, while 44% had some improvement 
in cognition/attention.  In non-ADHD subjects, 30% had worsening mood and/or anxiety 
symptoms, while 30% had some improvement in cognition/attention.  
  In conclusion, we found that most people (61%) treated with amphetamine 
stimulants identified in a mood specialty clinic were diagnosable with affective 
temperaments, especially cyclothymia. Amphetamine stimulant worsened mood/anxiety 
symptoms in about one-half of subjects, and improved cognition symptoms only about 
one-third subjects.  Prior ADHD diagnosis was associated with somewhat improved 
cognitive, but not mood/anxiety, outcomes. These results suggest that amphetamine 
stimulant treatment in an affectively ill population may have harmful mood/anxiety 
effects, and has only partly beneficial cognitive effects.  
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INTRODUCTION  
 
  Contemporary American psychiatry bases diagnoses on the DSM-III through 5 
system, which is characterized by being purely descriptive of symptoms (1).  Further, 
overlapping symptoms are present in many diagnoses, and are accepted as “comorbidities” 
(2).  This leads to the scenario where mood symptoms, for instance, can cause anxiety or 
inattention, and yet patients are diagnosed with multiple diagnoses of mood disorders, 
anxiety disorder, and attention deficit hyperactivity disorder (ADHD).  In contrast, before 
the current DSM approach began to be used in 1980 with the 3rd revision, a century or more 
of psychiatric research was based on the classic medical tradition of diagnosing as few 
conditions as possible (3).  Thus, since mood conditions can cause anxiety and inattention, 
only mood diagnoses would be made even if anxiety and inattention symptoms are present.  
Further, diagnoses were based on the course of illness and other factors, like genetics, not 
just symptoms alone, as in the DSM system (4). 
  This contrast plays in current psychiatric practice around the diagnosis of ADHD 
in particular, since inattention can be caused by other illnesses (such as mood and anxiety 
conditions). In this paper, we specifically address the concept of affective temperaments, 
which were seen for much of the 19th and 20th centuries, as mild versions of mood illnesses.  
Manic-depressive illness was the overarching mood illness, with either manic or depressive 
episodes as its main feature (5,6). In those patients and their relatives, it was noted that 
many persons had constant mild manic or depressive symptoms all the time, as part of their 
personalities (7).  This was called affective temperaments, with mild manic symptoms 
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(hyperthymia), mild depressive symptoms (dysthymia), or both (cyclothymia). (These 
conditions are defined in more detail below.) 
  In recent years, the diagnosis of ADHD has been extended from children to adults 
in the 5th revision of DSM (DSM-5) (8), and it is increasingly diagnosed and treated with 
amphetamine a potent central nervous stimulants . The latter agents have been shown to 
cause mania or worsen bipolar illness (9,10). In this study, we sought to identify and 
describe the potential mis-attribution of ADHD diagnosis and treatment to individuals with 
dysthymic and cyclothymic temperaments. We will then comment on the potential 
worsening of mood and anxiety in misdiagnosed individuals as well as on the lack of 
improvement in cognitive domains in misdiagnosed ADHD individuals with 
temperamentally significant dysthymia and cyclothymia.    
 
Affective temperaments defined  
 
  At one level affective temperament can be defined as mild version of mood states 
or sub-affective personality conditions or sub-syndromal manifestation of the illnesses. 
(11,7). It includes basic differences in personality traits and energy levels as expressed in 
sleep patterns and sexual and social behaviors or work related activities. The three basic 
temperaments are described as following:  
  Hyperthymia involves mild manic symptoms as part personality. Such persons are 
high in energy, need less sleep than most people (often 4-6 hours), have high sex drives, are 
highly social, extroverted, often workaholics, fast thinking, possibly higher consumption of 
alcohol, cigarettes, coffee, spend more money, and are often humorous. They are described 
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as the life of the party, fun, loving and can also engage in risk taking or reckless behaviors 
that others often avoid, such as skydiving or bungee jumping. They dislike routine and are 
spontaneous. They can be quite anxious and inattentive (12,13). 
  Dysthymia is a mild depressive state as part of one’s personality. Such persons are 
characterized as low energy, need more sleep than most people (9-11 hours), have low sex 
drive, prone to excessive worrying. It also includes preoccupation with personal failure. 
They avoid risk-taking behaviors and are devoted to routine. They can be quite anxious but 
not inattentive (12,14,15). 
  Cyclothymia involves a constant alternation between mild manic and depressive 
states on a day- to –day, or a few days at time, basis that fail to meet duration for major 
affective syndromes. Such persons go up and down in mood and energy as well in activity 
levels. They are generally extroverted, exhibiting high productivity, as well as highly social 
and risk-taking behavioral tendencies. Sometimes, those people are unpredictable and 
spontaneous. The core features in the majority of them include lability, anger and 
irritability. Inattention is very common (14).  
  The prevalence of mood temperaments relies on the cut off of 50 or 39 items                                                                      
of Temperament Scale of Memphis, Pisa, Paris and San Diego-Autoquestionnaire 
(TEMPS-A); a validated research scale for temperaments. Both of them have a very high 
and similar coefficient alpha. In statistics Cronbach’s alpha is used to estimate the 
reliability of a scale. It can be viewed as the expected correlation of two scales that measure 
the same construct.  Cyclothymic 0.88 for 50 items and 0.91, for 39 items. Hyperthymic, 
0.81 and 076. Dysthymic, 0.76 and 0.81 (12,16,17). In one study, they were defined as 75% 
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or more items being endorsed on the TEMPS-A. Using this definition, about 40% of 
subjects in a mood disorder clinic met the definition of cyclothymia. About 15% met the 
definition of hyperthymia and 10% were definable as dysthymia. About 50% of the 
subjects did not have any full mood temperament. If the cut off is put at lower threshold of 
50% of items, then the majority of subjects with mood conditions, like bipolar illness and 
major depression disorder meet the definition of mood temperament (18). Population 
prevalence studies are limited, but genetics studies that have looked at mood temperaments 
have noted that they are the most frequent finding in family members of persons with mood 
illness. These family members do not have full-blown depressive or manic episodes. (19). 
Thus, since mood conditions occur in about 5-10% of the general population in the Unites 
States (major depressive disorder and bipolar disorder) (20,21). One could infer that 
affective temperaments occur in a large number; perhaps a conservative estimate would be 
10-20% of the general population in the United States. In many cases, affective 
temperament occurs by themselves, meaning that no other diagnoses are present. In other 
cases, they occur as the baseline temperament in between full depressive or manic episodes 
in persons with mood illnesses. 
  This study has one particular outcome of interest.  That outcome is stimulant 
response in two domains. Mood/ anxiety and cognition/attention assessed using the Clinical 
Global Impression Scale –Improvement (CGI-I), in a population using any amphetamine 
approved by the FDA for ADHD treatment and affective temperament. Understanding that 
this is new approach to look at the inattention symptom shedding light on a possible new 
pathway of knowledge to approach the treatment and ADHD diagnosis. How is the 
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amphetamine response in this population going to reflect on the treatment of ADHD in the 
future? The hypothesis is that amphetamine would worsen in the mood/anxiety domain and 
at least be ineffective in the cognitive domain.   
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METHODS  
 
  This study followed the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement (22).  Charts of all outpatients treated in the Tufts 
Medical Center Mood Disorders Program were reviewed to identify all subjects treated 
with any amphetamine or stimulant medication approved by FDA to treat ADHD 
(Methylphenidate, dextroamphetamine, dexmethylphenidate, lisdexamfetamine). Also, 
another inclusion was presence of a completed TEMPS-A scale (50 items or 39 items). 
This scale was validated in more than 25 languages, to access temperament types as 
cyclothymic, dysthymic and hyperthymic, as explained in more details in the introduction 
(23). 87 subjects with 18 years or above from a population of 770 patients treated in the 
program were included in this study (Figure 1). Their charts were reviewed for the 
following clinical and demographic variables: age, sex, ethnicity, marital status, 
employment, education level, family history, psychosis and mania history, the average time 
of amphetamine use, and diagnosis after evaluation in Mood Disorders Program. Tufts 
Medical Center Institutional Review Board approval to conduct this chart review was 
obtained.  
  Amphetamine response was accessed in relation to cognition/attention and in 
relation to mood/anxiety by a Clinical Global Impression improvement (CGI-I) rating 
scale. The CGI-I ratings were ascertained retrospectively at the time of chart review by 2 
psychiatrist/researchers with expertise in mood disorders (Sivan Mauer MD and Nassir 
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Ghaemi MD). After completing independent ratings, consensus was established for each 
patient for any ratings that differed. The CGI-I scale assesses the extent of clinical change 
in the patient at the point of assessment compared with baseline, using a 7 point range from 
“ very much improved” 1 to “very much worse” 7 (24). From May to July 2016 data was 
collected using REDCap, a research electronic data capture (25).  
 
Statistical Analyses 
   Statistical analyses included descriptive statistics, stratification, and chi-square 
test to compare the treatment response between the two groups in both domains 
(mood/anxiety and cognition). TEMPS-A was used as a dichotomous measure with 50% 
and 75% of cut off. The sample was stratified between subjects that had ADHD diagnosis 
and those who did not have any official diagnosis of ADHD in their lives. All analyses 
were made using “R” version 3.2.4 software (26).   
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RESULTS 
 
  Table 1 provides clinical and demographic characteristics of the sample. About 
one-half of the sample was diagnosed with ADHD at some point in the past, and on-half 
was not.  The majority of both groups were white and unemployed. The ADHD group was 
younger. Most of the non-ADHD group lived alone and had higher education level. Family 
history of bipolar disorder was present in half of subjects in both groups. Average time of 
amphetamine use was more than double in the ADHD group.  After research-based 
diagnostic evaluation, about 90% of the sample was diagnosed with bipolar disorder. 
26% of the ADHD group had at least one manic/hypomanic episode caused by 
amphetamine use versus 16% in the non-ADHD group.  21% of subjects overall had 
amphetamine-related manic/hypomanic episodes.    
   Using the 50% item threshold, temperaments were common, with highest 
prevalence for cyclothymia, followed by hyperthymia and then dysthymia in the ADHD 
group.  In the non-ADHD group, there was also high prevalence of cyclothymia, followed 
by dysthymia and then hyperthymia.   Very few people were not diagnosable with any 
temperament. Using the 75% item threshold, the most prevalent temperament in both 
groups was cyclothymia, the prevalence of hyperthymia in the ADHD group was almost 
double the non-ADHD group, and 45% of non-ADHD subjects and 32% of ADHD 
subjects did not have any kind of temperament. In the total sample 61% had an affective 
temperament using the definition of 75% TEMPS-A items endorsed. Of these, the most 
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common kind of temperament was cyclothymic (40%) and hyperthymic (24%). Affective 
temperaments are not mutually exclusive; there is less overlap with higher cut-off 
thresholds.   
    Regarding treatment response, using the CGI-I, in ADHD subjects 49% showed 
worsened mood/anxiety; 44% showed no benefit for cognition/attention (Table 2, Figure 2, 
and Figure 3). In non-ADHD subjects 30% had worsened mood/anxiety, and most of this 
group also showed no benefit for cognition/attention, with somewhat more than one-quarter 
showing some improvement (Table 2, Figure 4 and Figure 5).  In the total sample 43% had 
worsened mood /anxiety symptoms, and 37% of subjects had mild or moderate 
improvement in cognition  (Table 2,Figure 6, Figure7).  The chi-square statistic in both 
domains is small (5.39 in mood / anxiety and 2.04 in cognition) meaning that in this sample 
the amphetamine response is not associated with ADHD diagnosis (Table 2).   
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DISCUSSION 
 
  This is the first study that correlates the three main types of temperament and 
amphetamine response. Three kinds of temperament, especially cyclothymia, were 
prevalent notably in this sample. Amphetamine response was poor, with worsening of 
mood/anxiety in most cases, and little benefit for cognition/attention in our sample.  About 
one-fifth of patients with affective temperaments experience amphetamine-related manic 
episodes. One clinical implication of these results is that adult ADHD diagnosis, and/or 
prescription of amphetamine stimulants, may occur in some cases in the setting of 
misdiagnosis of affective temperaments. Another possibility could be that cyclothymia is a 
common temperament in both bipolar disorder and ADHD.  
  There is only one prior study of temperament association with ADHD diagnosis, 
with similar findings.  In that case-control study in Norway, 586 clinically diagnosed 
subjects with adult ADHD were compared to 721 controls. Using the 50% item cut off 
TEMPS definition, 71% of subjects with ADHD and 13% of controls were classified as 
having cyclothymic temperament. In both studies the “comorbidity” with mood illness are 
higher in the ADHD group, being present in almost 80% (27).   
  There are no prior studies of amphetamine outcomes related to affective 
temperaments and ADHD.  There are prior studies of amphetamines in bipolar disorder and 
ADHD comorbidity, with some showing efficacy, and some showing no benefit (28–31). 
An example of the latter type of study is a randomized crossover trial of methylphenidate 
and placebo combined with aripiprazole in 16 children and adolescents with bipolar 
		
11	
disorder and ADHD, in which methylphenidate was not more effective than placebo (32).  
These results would be consistent with our finding that most of subjects of both groups did 
not have improvement in cognition.    
  No prior study has assessed mood/anxiety effects, separately from cognitive 
effects, with affective temperaments and ADHD.  Few studies of bipolar disorder and 
ADHD comorbidity exist which assess mood outcomes with amphetamine stimulants for 
mood.  For example, one retrospective chart review with 16 adult patients with bipolar 
illness who were prescribed methylphenidate for any reason found improvement in mood 
related symptoms (33).  A prospective cohort study from the same group with 14 adult 
patients with bipolar depression met a decrease in depression symptoms in the Hamilton 
depression scale (34). The only other study to assess amphetamine-related mania in adults 
reported that it occurred in 40% of subjects (n=137) with bipolar disorder (mean age 38.8 
years) (10). In a retrospective chart review of 82 bipolar children (mean age of 10.6 years), 
24% of the sample had manic or hypomanic episodes with amphetamines (35), similar to 
our study where 21% of total sample experienced mania or hypomania with amphetamines. 
Also almost half of subjects in the ADHD group experienced worsened mood symptoms 
with amphetamines. Only 2% of subjects experienced mood or anxiety improvement in the 
ADHD group, and none in the non-ADHD group.  
  This study has several limitations. The sample was not randomized; the data are 
open, uncontrolled and retrospective. Former psychiatrist/clinicians made the diagnosis of 
ADHD clinically, without using validated diagnostic interviews. The non-controlled design 
of this study did not allow for comparisons to subjects not treated with amphetamines. The 
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naturalistic context of treatment, especially concomitant use of other medications, could 
introduce confounding treatment effects in the assessment of amphetamine treatment 
response or side effect perception. Since 78% of subjects were Caucasian, these results may 
not be generalizable to other ethnic groups.  
  In conclusion, a relationship appears to exist between cyclothymic and 
hyperthymic temperaments in subjects treated with amphetamines.  Stimulant response was 
neutral in the majority of these subjects in relation of mood/ anxiety or cognition attention, 
with some worsening in subjects diagnosed with ADHD. These results may indicate that 
adult ADHD is misdiagnosed in some persons who have hyperthymic or cyclothymic 
affective temperaments.  Further amphetamines seem mostly ineffective or even harmful in 
these patients. Future research could build on these pilot data with larger samples and more 
valid research designs, and with non-stimulant control groups.  These could include case-
control studies or prospective cohort studies with large numbers of subjects, with and 
without ADHD diagnosis, with and without stimulant treatment, and assessed with 
validated scales for affective temperaments and ADHD, as well as validated scales for 
treatment response. Further, randomized clinical trials could be conducted in patients with 
affective temperaments of cyclothymic and/or hyperthymia, randomized to stimulant 
treatment versus placebo, to assess mood and cognitive treatment response.  A comparator 
arm of mood stabilizer treatment could be included as well to see if such treatment is equal 
to, better than, or worse than stimulant medications in this population. 
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Table 1.Demographic Characteristic of the sample (n=87) 
 ADHD N=43 Not ADHD N=44 Total (87) 
Age (SD) 30.1±11.7 39.8 ±14.2 35±13.8 
Gender Male (%) 56 52 54 
Marital status- single 
(%) 
77 55 66 
Ethnicity-White (%)  79 77 78 
Unemployed (%)  67 55 61 
Education level   (%) 33- HS 25- BA 28-BA 
Lives alone (%) 19 36 28 
Dysthymic 50(%) 41 48 45 
Cyclothymic 50(%) 70 61 66 
Hyperthymic 50(%) 51 43 47 
None(%) 5 7 6 
Dysthymic 75(%) 21 18 20 
Cyclothymic 75 (%) 44 36 40 
Hyperthymic 75(%) 30 18 24 
None(%) 32 45 39 
Family HX Bipolar I 50 50 49 
Unipolar Depression  25 20 23 
Schizophrenia  13 4.5 8 
Past Trauma 12 16 14 
Past psychosis  14 23 18 
Diagnosis BD (%) 95 89 92 
Manic episode (%) 26 16 21 
Average time use 
amphetamine weeks 
(SD) 
236.5 ±205 108 ±128.7 180±185.7 
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Table 2 Percentages of amphetamine response in Cognition and Mood/anxiety 
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Table 2 Percentages of amphetamine response in Cognition and Mood/anxiety  
!!=Chi-Square test 
 
 
 
 
 
 
 
  
 
 Total (87) 
CGI 
Mood/ 
Anxiety 
Total (87) 
Cognition 
Non-
ADHD 
(n=44) 
CGI 
Mood/ 
Anxiety  
ADHD 
(44) 
Mood/ 
Anxiety 
 
ADHD 
(n=43) 
CGI 
Cognition  
 Non- 
ADHD 
(43) 
Cognition 
   !!=5.39 p=0.07 !!=2.04 p=0.36 
Improvement (%) 2 37 0 7 44 29.6 
No Change (%) 55 63 64 44 56 70.4 
Worse (%) 43 0 36 49 0 0 
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Fig.1 Subject’s inclusion/exclusion criteria flowchart  
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Figure 3 
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Figure 4 
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Figure 5 
 
 
Figure 6 
 
0%	
27.30%	
2.30%	
70.40%	
0.00%	 0.00%	 0%	0%	10%	
20%	30%	
40%	50%	
60%	70%	
80%	
Very	Much	Improved	 Much	Improved	 Minimally	Improved	 No	change	 Minimally	Worse	 Much	Worse	 Very	Much	Worse	
CGI	Cognition	Non-	ADHD	CGI	Cognition	Non-	ADHD	
0%	 0.00%	 2.00%	
55.00%	
15.00%	 20.00%	 8%	
0%	10%	
20%	30%	
40%	50%	
60%	
Very	Much	Improved	 Much	Improved	 Minimally	Improved	 No	change	 Minimally	Worse	 Much	Worse	 Very	Much	Worse	
CGI	Mood/Anxiety	Total	CGI	Mood/Anxiety	Total	
		
20	
 
Figure 7 
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